Synovial sarcoma: Report of a series of 25 consecutive children from a single institution

Andrea Ferrari, Michela Casanova, Maura Massimino, Roberto Luksch, Graziella Cefalo, Fabrizio Lombardi, Stefania Galimberti, Giorgia Riganti, Franca Fossati-Bellani

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background. The role of postoperative radiotherapy and adjuvant chemotherapy in the treatment of synovial sarcoma remains to be determined. Procedure. Twenty-five children were treated during a 23-year period with a multimodality approach. All of them had resection of the primary tumor (three amputations), followed by surgical retreatment in eight. Postoperative radiotherapy was delivered to 16 patients and adjuvant chemotherapy was given to 22. Results. At the time of the report, 19 patients were alive and without evidence of disease. Six developed distant metastases (one associated with local recurrence); five of them died of their disease and one was alive in complete remission at 4 years from relapse. With a median follow-up of 9 years (range 2-23), the survival and the event-free survival at 5 years were 80% (SE 8.2) and 74% (SE 9.2), respectively. All relapsing patients had been classified as T2B. Conclusions. Multimodality treatment yielded satisfying survival results using limbpreserving surgery in most cases. Tumor size >5 cm and invasiveness, which defined stage T2B, were the most important predictors of poor outcome. Evaluation of the role of adjuvant chemotherapy and radiotherapy awaits prospective studies, even if T2B patients, as well as children having nonradical surgery, seem worth managing by adjuvant treatments.

Original languageEnglish
Pages (from-to)32-37
Number of pages6
JournalMedical and Pediatric Oncology
Volume32
Issue number1
DOIs
Publication statusPublished - Jan 1999

Fingerprint

Synovial Sarcoma
Adjuvant Chemotherapy
Radiotherapy
Recurrence
Adjuvant Radiotherapy
Retreatment
Survival
Amputation
Disease-Free Survival
Neoplasms
Therapeutics
Prospective Studies
Neoplasm Metastasis

Keywords

  • Pediatric cancer
  • Soft tissue sarcoma
  • Synovial sarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Cite this

Synovial sarcoma : Report of a series of 25 consecutive children from a single institution. / Ferrari, Andrea; Casanova, Michela; Massimino, Maura; Luksch, Roberto; Cefalo, Graziella; Lombardi, Fabrizio; Galimberti, Stefania; Riganti, Giorgia; Fossati-Bellani, Franca.

In: Medical and Pediatric Oncology, Vol. 32, No. 1, 01.1999, p. 32-37.

Research output: Contribution to journalArticle

Ferrari, Andrea ; Casanova, Michela ; Massimino, Maura ; Luksch, Roberto ; Cefalo, Graziella ; Lombardi, Fabrizio ; Galimberti, Stefania ; Riganti, Giorgia ; Fossati-Bellani, Franca. / Synovial sarcoma : Report of a series of 25 consecutive children from a single institution. In: Medical and Pediatric Oncology. 1999 ; Vol. 32, No. 1. pp. 32-37.
@article{08c935883ce24e47afb170b4078899c8,
title = "Synovial sarcoma: Report of a series of 25 consecutive children from a single institution",
abstract = "Background. The role of postoperative radiotherapy and adjuvant chemotherapy in the treatment of synovial sarcoma remains to be determined. Procedure. Twenty-five children were treated during a 23-year period with a multimodality approach. All of them had resection of the primary tumor (three amputations), followed by surgical retreatment in eight. Postoperative radiotherapy was delivered to 16 patients and adjuvant chemotherapy was given to 22. Results. At the time of the report, 19 patients were alive and without evidence of disease. Six developed distant metastases (one associated with local recurrence); five of them died of their disease and one was alive in complete remission at 4 years from relapse. With a median follow-up of 9 years (range 2-23), the survival and the event-free survival at 5 years were 80{\%} (SE 8.2) and 74{\%} (SE 9.2), respectively. All relapsing patients had been classified as T2B. Conclusions. Multimodality treatment yielded satisfying survival results using limbpreserving surgery in most cases. Tumor size >5 cm and invasiveness, which defined stage T2B, were the most important predictors of poor outcome. Evaluation of the role of adjuvant chemotherapy and radiotherapy awaits prospective studies, even if T2B patients, as well as children having nonradical surgery, seem worth managing by adjuvant treatments.",
keywords = "Pediatric cancer, Soft tissue sarcoma, Synovial sarcoma",
author = "Andrea Ferrari and Michela Casanova and Maura Massimino and Roberto Luksch and Graziella Cefalo and Fabrizio Lombardi and Stefania Galimberti and Giorgia Riganti and Franca Fossati-Bellani",
year = "1999",
month = "1",
doi = "10.1002/(SICI)1096-911X(199901)32:1<32::AID-MPO7>3.0.CO;2-1",
language = "English",
volume = "32",
pages = "32--37",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Synovial sarcoma

T2 - Report of a series of 25 consecutive children from a single institution

AU - Ferrari, Andrea

AU - Casanova, Michela

AU - Massimino, Maura

AU - Luksch, Roberto

AU - Cefalo, Graziella

AU - Lombardi, Fabrizio

AU - Galimberti, Stefania

AU - Riganti, Giorgia

AU - Fossati-Bellani, Franca

PY - 1999/1

Y1 - 1999/1

N2 - Background. The role of postoperative radiotherapy and adjuvant chemotherapy in the treatment of synovial sarcoma remains to be determined. Procedure. Twenty-five children were treated during a 23-year period with a multimodality approach. All of them had resection of the primary tumor (three amputations), followed by surgical retreatment in eight. Postoperative radiotherapy was delivered to 16 patients and adjuvant chemotherapy was given to 22. Results. At the time of the report, 19 patients were alive and without evidence of disease. Six developed distant metastases (one associated with local recurrence); five of them died of their disease and one was alive in complete remission at 4 years from relapse. With a median follow-up of 9 years (range 2-23), the survival and the event-free survival at 5 years were 80% (SE 8.2) and 74% (SE 9.2), respectively. All relapsing patients had been classified as T2B. Conclusions. Multimodality treatment yielded satisfying survival results using limbpreserving surgery in most cases. Tumor size >5 cm and invasiveness, which defined stage T2B, were the most important predictors of poor outcome. Evaluation of the role of adjuvant chemotherapy and radiotherapy awaits prospective studies, even if T2B patients, as well as children having nonradical surgery, seem worth managing by adjuvant treatments.

AB - Background. The role of postoperative radiotherapy and adjuvant chemotherapy in the treatment of synovial sarcoma remains to be determined. Procedure. Twenty-five children were treated during a 23-year period with a multimodality approach. All of them had resection of the primary tumor (three amputations), followed by surgical retreatment in eight. Postoperative radiotherapy was delivered to 16 patients and adjuvant chemotherapy was given to 22. Results. At the time of the report, 19 patients were alive and without evidence of disease. Six developed distant metastases (one associated with local recurrence); five of them died of their disease and one was alive in complete remission at 4 years from relapse. With a median follow-up of 9 years (range 2-23), the survival and the event-free survival at 5 years were 80% (SE 8.2) and 74% (SE 9.2), respectively. All relapsing patients had been classified as T2B. Conclusions. Multimodality treatment yielded satisfying survival results using limbpreserving surgery in most cases. Tumor size >5 cm and invasiveness, which defined stage T2B, were the most important predictors of poor outcome. Evaluation of the role of adjuvant chemotherapy and radiotherapy awaits prospective studies, even if T2B patients, as well as children having nonradical surgery, seem worth managing by adjuvant treatments.

KW - Pediatric cancer

KW - Soft tissue sarcoma

KW - Synovial sarcoma

UR - http://www.scopus.com/inward/record.url?scp=0032953485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032953485&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-911X(199901)32:1<32::AID-MPO7>3.0.CO;2-1

DO - 10.1002/(SICI)1096-911X(199901)32:1<32::AID-MPO7>3.0.CO;2-1

M3 - Article

C2 - 9917750

AN - SCOPUS:0032953485

VL - 32

SP - 32

EP - 37

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 1

ER -